Latest:
Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer
Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Costanza Lo Cascio, PhD
Latest:
A New Take on Preclinical Drug Trials for GBM Treatment
The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to subvert this pattern of clinical failure for promising therapeutics by changing the way preclinical studies are developed and conducted to assess the efficacy of drugs for GBM.
Efstathios Kastritis, MD
Latest:
Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.
Timothy I Shaw, PhD
Latest:
Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors
Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.
Nicholas J. Short, MD
Latest:
Understanding How to Best Measure MRD Negativity in Ph+ ALL
The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
Timothy Cloughesy, MD
Latest:
INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation
Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.
Christian Grohe, MD, Evangelical Lung Cancer Hospital
Latest:
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.